Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?

BACKGROUND: A significant amount of common variable immunodeficiency (CVID) patients manifest with autoimmunity. Particularly, autoimmune thrombocytopenia (AITP) is commonly seen. Intravenous immunoglobulins (IVIG) are an established treatment option for both, CVID and AITP. Nonetheless, due to fewe...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Front Immunol
Main Authors: Scheuerlein, Philipp, Pietsch, Larissa, Camacho-Ordonez, Nadezhda, Reiser, Veronika, Patel, Smita, Burns, Siobhan O., Warnatz, Klaus, Grimbacher, Bodo
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2018
Teme:
Immunology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6060403/
https://ncbi.nlm.nih.gov/pubmed/30072997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.01656
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki